Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows - Moderna ( NASDAQ:MRNA )
Moderna Inc. MRNA is developing mRNA-1769 as a mpox vaccine for use in adults. Currently, a Phase 1/2 trial evaluating the safety, tolerability, and immunogenicity of mRNA-1769 in Healthy Participants is underway. The 351-subject trial was started in 2023, and data is anticipated in 2025.
| Ticker |
Sentiment |
Impact |
|
MRNA
|
Neutral
|
36 %
|
|
BNTX
|
Neutral
|
25 %
|
|
BVNKF
|
Somewhat Bearish
|
25 %
|
